Gemcitabine/Cisplatin is named as a drug or biological intervention in 8 clinical trials in our China, UK, USA and India trial registers, 6 of which are recruiting. Lead sponsors include AstraZeneca (2), First Affiliated Hospital of Zhejiang University (1) and Wei Jiang (1). Registered phases: Phase 3, Phase 1, Phase 2 and Phase 1/2. Conditions studied include Biliary Tract Cancer; Nasopharyngeal Carcinoma; Bile Duct Carcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Biliary Tract Cancer | 3 |
| Nasopharyngeal Carcinoma | 2 |
| Bile Duct Carcinoma | 1 |
| Gall Bladder Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Recurrent Non-small Cell Lung Cancer | 1 |
| Intrahepatic Cholangiocarcinoma (Icc) | 1 |
| Muscle Invasive Bladder Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 2 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Wei Jiang | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Shanghai 6th People's Hospital | 1 |
| Air Force Military Medical University, China | 1 |
| First Affiliated Hospital of Chongqing Medical University | 1 |
| Register | Gemcitabine/Cisplatin trials |
|---|---|
| Clinical trials in China | 8 |
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in India | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine/Cisplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine/Cisplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.